Last $174.42 USD
Change Today +4.33 / 2.55%
Volume 1.1M
As of 5:20 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

Fourth Floor

One Burlington Road

Dublin, 4


Phone: 353 1 634 7800


mplication of hematopoietic stem cell transplantation (HSCT) that afflicts up to 50% of all donor transplant patients. Defitelio is available in approximately 40 countries through 10 distribution partnerships on a named patient basis. Under a license and supply agreement, Gentium has licensed the rights to commercialize defibrotide for the treatment and prevention of VOD in North America, Central America and South America, subject to receipt of marketing authorization in the applicable territory, if any, to Sigma-Tau Pharmaceuticals, Inc., or Sigma-Tau. The company has a portfolio of U.S. and non-U.S. patents and patent applications relating to various compositions of defibrotide, methods of use and methods of characterization, which would expire at various times between April 2017 and June 2032. One patent that issued in the United States and other countries covers the method for determining the biological activity of defibrotide. This patent expires in November 2022 in most countries. Prialt (ziconotide) intrathecal infusion Prialt is an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Intrathecal therapy is the delivery of the drug into the intrathecal space in the spine through an infusion system comprising a programmable infusion pump and catheter. Ziconotide is a synthetic neuroactive peptide known as conotoxin and is the synthetic equivalent of a naturally-occurring conopeptide found in the piscivorous marine snail, Conus Magus. Prialt is the only FDA-approved non-opioid intrathecal analgesic. Azur Pharma acquired the rights to Prialt from Elan Pharmaceuticals, Inc. (subsequently acquired by Perrigo Company plc), or Elan, in 2010. Pursuant to an asset purchase agreement executed between Azur Pharma and Elan in 2010, Azur Pharma acquired worldwide rights to Prialt excluding those territories licensed by Elan to Eisai Co. Limited, or Eisai, which consist of 34 countries outside of the United States, mainly in Europe. The company supplies Prialt to Eisai. In 2013, the company expanded its collaboration with Medtronic Inc., the maker of SynchroMed II programmable implantable pumps approved by the FDA for use with Prialt, to enhance its ability to access physicians and provide education regarding the use of Prialt. The company has three U.S. patents covering Prialt, which would expire from June 2015 to December 2016. Psychiatry Products The company markets FazaClo HD and FazaClo LD, each of which is an orally disintegrating tablet formulation of clozapine that is indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment for schizophrenia and for reduction in the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. In February 2014, the company launched Versacloz, an oral suspension formulation of clozapine, for treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorders. Versacloz was approved by the FDA for both indications in February 2013. The company has a license and supply agreement with Douglas Pharmaceuticals America Limited, or Douglas Pharmaceuticals, and obtained an exclusive license to market, distribute and sell Versacloz in the United States and Mexico from Douglas Pharmaceuticals. An authorized generic version of FazaClo LD launched in 2012. Other clozapine generics are referenced to Clozaril, a standard immediate release tablet formulation of clozapine from Novartis Pharmaceuticals Corporation. FazaClo HD and FazaClo LD incorporate the DuraSolv orally disintegrating tablet technology that the company licenses from CIMA Labs Inc., or CIMA, a subsidiary of Teva Pharmaceutical Industries Limited, or Teva, which


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JAZZ:US $174.42 USD +4.33

JAZZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $53.71 USD -0.10
BioMarin Pharmaceutical Inc $108.42 USD +1.35
Impax Laboratories Inc $40.45 USD +0.16
Sagent Pharmaceuticals Inc $27.88 USD +0.70
Salix Pharmaceuticals Ltd $156.88 USD -0.32
View Industry Companies

Industry Analysis


Industry Average

Valuation JAZZ Industry Range
Price/Earnings 100.0x
Price/Sales 8.8x
Price/Book 7.5x
Price/Cash Flow 55.8x
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at